Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

The Washington University

Status: Enrolling

Conditions: Glioblastoma; Glioblastoma Multiforme

Treatments: Device: Sonobiopsy; Procedure: Research blood; Device: Definity®; Genetic: Cancer Personalized Profiling

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05281731

R01CA276174 (U.S. NIH Grant/Contract)

202202025

Details and patient eligibility

About

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment.
• Lesion must be > 3 cm in maximal dimension on MRI.
• Lesion must be in the supratentorial space within 5 cm of the cortical surface.
• Lesion must be gadolinium enhancing.
• Low grade tumors and metastatic tumors
• Recurrent brain tumors and/or radiation necrosis
• Must be planning to undergo surgical resection of the tumor.
• Must be at least 18 years old.
• Patients with recurrent GBM who are planning to undergo surgical resection or laser ablation of the recurrent tumor. Recurrence must be confirmed on MRI performed no more than 28 days prior to enrollment.

Exclusion criteria

• Contraindication to MRI.
• Previous cranial surgery.
• Previous history of cancer and/or cancer treatments.
• Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets < 100,000/mcL.
• Physical skull defect of any kind.
• Ferrous material in the scalp or skull.
• Scalp or skin disease that limits contact with the ultrasound probe.
• Enrolled in another clinical trial where intervention is administered prior to surgery.
• Known hypersensitivity to polyethylene glycol.
• Known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias).

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Sonobiopsy

Experimental group

Description:

* Once enrolled, participants would be prepared for standard of care surgery. * The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur. * An additional brief MRI scan will be obtained using the intraoperative MRI to define imaging changes (if any) that occur as a result of the sonobiopsy procedure. The imaging protocols will include a 3D T2-weighted (T2w) scan, and 3D contrast T1-weighted (T1w) with dynamic contrast enhancement and if time allows T2\* sequence. * Blood will be collected at several time points. * A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor. * The blood, tumor, and skin (if applicable) will undergo genetic analysis.

Treatment:

Genetic: Cancer Personalized Profiling

Device: Definity®

Procedure: Research blood

Device: Sonobiopsy